Brokerages Anticipate Inflarx NV (NASDAQ:IFRX) to Announce -$0.60 Earnings Per Share
Wall Street analysts expect Inflarx NV (NASDAQ:IFRX) to announce ($0.60) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Inflarx’s earnings. The lowest EPS estimate is ($0.72) and the highest is ($0.53). Inflarx reported earnings of ($0.31) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 93.5%. The company is expected to issue its next quarterly earnings report on Wednesday, November 20th.
On average, analysts expect that Inflarx will report full-year earnings of ($2.25) per share for the current financial year, with EPS estimates ranging from ($2.54) to ($2.09). For the next financial year, analysts forecast that the business will post earnings of ($2.75) per share, with EPS estimates ranging from ($4.02) to ($2.14). Zacks’ earnings per share averages are an average based on a survey of analysts that cover Inflarx.
Inflarx (NASDAQ:IFRX) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.11).
IFRX traded down $0.02 during mid-day trading on Wednesday, reaching $2.29. 2,620 shares of the stock were exchanged, compared to its average volume of 783,524. The stock has a market capitalization of $59.98 million, a PE ratio of -1.63 and a beta of -1.51. The company has a 50 day moving average price of $2.73 and a two-hundred day moving average price of $17.86. Inflarx has a 1 year low of $2.17 and a 1 year high of $53.10.
Hedge funds and other institutional investors have recently modified their holdings of the company. Acadian Asset Management LLC purchased a new stake in Inflarx in the second quarter worth approximately $445,000. Atria Investments LLC purchased a new stake in shares of Inflarx during the second quarter valued at approximately $297,000. A.R.T. Advisors LLC boosted its stake in shares of Inflarx by 145.8% during the second quarter. A.R.T. Advisors LLC now owns 29,162 shares of the company’s stock valued at $92,000 after purchasing an additional 17,300 shares during the period. Alpine Global Management LLC purchased a new stake in shares of Inflarx during the second quarter valued at approximately $95,000. Finally, Redmile Group LLC boosted its stake in shares of Inflarx by 7.2% during the first quarter. Redmile Group LLC now owns 2,182,638 shares of the company’s stock valued at $82,482,000 after purchasing an additional 147,238 shares during the period. 17.06% of the stock is owned by institutional investors.
Inflarx Company Profile
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Featured Article: Most Volatile Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.